DIAN-TU Primary Prevention of Dominantly Inherited Alzheimer’s Disease
Official title: DIAN-TU Primary Prevention Trial
Funded at Washington University · NIH-11579120 · Data updated 2026-11-12
A global effort is testing a preventive treatment to help people who are certain to develop a form of Alzheimer’s disease long before symptoms start.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 15, 2018 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $68,373 |
| NIH project number | 3R01AG059798-06S2 |
| Project ID | NIH-11579120 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with a dominantly inherited Alzheimer’s mutation, currently asymptomatic and 11–25 years from expected symptom onset, with minimal amyloid plaque burden at entry.
✕Less likely to help
People who do not carry an AD dominantly inherited mutation or are beyond the early pre-symptomatic window may not benefit.
What this research studies
This trial platform targets individuals with dominantly inherited Alzheimer’s disease who are 11 to 25 years away from expected symptom onset. It uses a multi-stage, randomized, blinded design to evaluate remternetug and potentially other therapies in asymptomatic people with a genetic risk. The study is organized across 16 countries and 40 sites, with robust infrastructure to support early intervention and careful monitoring. Participants will receive treatment or placebo while researchers track cognitive function and biomarkers over time.
Why it matters
Potential benefit: If successful, the trial could delay or lessen cognitive decline for people at high genetic risk, potentially changing the course of the disease.
How similar studies have gone: Recent advances showing amyloid removal can slow cognitive decline support the approach, though primary prevention in this population is pioneering.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Mcdade, Eric Martin — Washington University
- Study coordinator: Mcdade, Eric Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.